Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > RealityCheck4U here - after 3+ years as TH holder
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(33)
•••
Comment by FredTheVoiceon Apr 18, 2021 4:17pm
111 Views
Post# 33019459

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RealityCheck4U here - after 3+ years as TH holder

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RealityCheck4U here - after 3+ years as TH holderAs always An-alias, non problem discussing and laughing a little at each other, its fair game !

But, as usual, I am not understanding all your arguments.

NASH in phase III is in the basket, and, we are a NASH player, with a drug that as proven safety and over all, results that are interesting. At one point, market and other pharma will pay attention. And that will be rewarded by market. And its soon.

Oncology, I must admit that its 50/50, but very promising and worth staying and puting more money here before phase 1 results. Because, there is a chance that it will be a real game changer !

I am very confident with 2021 for TH. Would I be desapointed with Oncology showing no good sign in human ? For sure, but NASH would still be rolling in phase III. And remember how TH paid for KATANA......

Lets see, wont take to long to see.....

CHEERS,

FTV.

 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities